

Patents, Profits, and the American People “The Bayh

New England Journal of Medicine

369, 794-796

DOI: 10.1056/nejmp1306553

Citation Report

#	ARTICLE	IF	CITATIONS
1	Patenting the PKU Test – Federally Funded Research and Intellectual Property. <i>New England Journal of Medicine</i> , 2013, 369, 792-794.	27.0	4
2	Conflict of interest in American neurology and neurological societies. <i>Neurology and Clinical Neuroscience</i> , 2014, 2, 65-71.	0.4	0
3	What Is the Public's Right to Access Medical Discoveries Based on Federally Funded Research?. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 907.	7.4	8
5	Replicated, replicable and relevant – target engagement and pharmacological experimentation in the 21st century. <i>Biochemical Pharmacology</i> , 2014, 87, 64-77.	4.4	28
6	Drug Development (and Academic Medicine): Charting the Course Forward. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 519-522.	4.7	3
7	MORE THAN MONEY: THE EXPONENTIAL IMPACT OF ACADEMIC TECHNOLOGY TRANSFER. <i>Technology and Innovation</i> , 2014, 16, 75-84.	0.2	27
8	Policy Commercializing Nonprofits in Health: The History of a Paradox From the 19th Century to the ACA. <i>Milbank Quarterly</i> , 2015, 93, 179-210.	4.4	12
9	Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study. <i>Milbank Quarterly</i> , 2015, 93, 761-787.	4.4	14
10	Intellectual Property, Scientific Independence, and the Efficacy and Environmental Impacts of Genetically Engineered Crops. <i>Rural Sociology</i> , 2015, 80, 147-172.	2.2	18
11	Science as a Social Enterprise. , 2015, , 291-336.		0
12	Translational Medicine. , 2015, , 313-325.		3
13	The Bayh-Dole Act, A Lion without Claws. <i>Clinical and Translational Science</i> , 2015, 8, 3-4.	3.1	2
14	Do You Own Your 3D Bioprinted Body?. <i>American Journal of Law and Medicine</i> , 2015, 41, 167-189.	0.2	13
15	Entrepreneurship in the Academic Radiology Environment. <i>Academic Radiology</i> , 2015, 22, 14-24.	2.5	16
16	Lessons Learned: Transfer of the High-Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 777-785.	4.7	5
17	A review of the progress and pitfalls of FDA policy process: Planning a pathway for pharmaceutical interventions for hearing loss development. <i>Hearing Research</i> , 2017, 349, 172-176.	2.0	4
18	The costs of patenting in Mexico. <i>Revista Médica Del Hospital General De México</i> , 2018, 81, 165-176.	0.0	3
19	Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh-Dole Act. <i>Academic Medicine</i> , 2018, 93, 1135-1141.	1.6	20

#	ARTICLE	IF	CITATIONS
20	Healing an ailing pharmaceutical system: prescription for reform for United States and Canada. BMJ: British Medical Journal, 2018, 361, k1039.	2.3	17
21	The Current Status of Drug Discovery and Development as Originated in <scp>United States</scp> Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development. Clinical and Translational Science, 2018, 11, 597-606.	3.1	135
22	Reproducibility in Biomedical Research. , 2018, , 1-66.		1
23	Entrepreneurialism in the TranslationalÂBiologic Sciences. JACC Basic To Translational Science, 2018, 3, 1-8.	4.1	0
25	Public sector financial support for late stage discovery of new drugs in the United States: cohort study. BMJ: British Medical Journal, 2019, 367, l5766.	2.3	42
26	Sharing with Strangers: Governance Models for Borderless Genomic Research in a Territorial World. Kennedy Institute of Ethics Journal, 2019, 29, 67-95.	0.5	9
27	Scientists Should Disclose Origin in Marine Gene Patents. Trends in Ecology and Evolution, 2019, 34, 392-395.	8.7	10
28	Bioelectronic Medicineâ€”Ethical Concerns. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034363.	6.2	5
29	Data Dissemination: Shortening the Long Tail of Traumatic Brain Injury Dark Data. Journal of Neurotrauma, 2020, 37, 2414-2423.	3.4	13
30	The Changing Structure of American Innovation: Some Cautionary Remarks for Economic Growth. Innovation Policy and the Economy, 2020, 20, 39-93.	4.7	46
31	Expanding roles for academic entrepreneurship in drug discovery. Drug Discovery Today, 2020, 25, 1905-1909.	6.4	10
32	Minimally Invasive Glaucoma Surgery: A Critical Appraisal of the Literature. Annual Review of Vision Science, 2020, 6, 47-89.	4.4	30
33	Proâ€”Con Perspectives on Ethics in Surgical Research: Update from the 39th Annual Surgical Infection Society Meeting. Surgical Infections, 2020, 21, 332-343.	1.4	2
34	Translational medicine: the changing role of big pharma. , 2021, , 441-450.		0
35	Amend Patent Legislation to Expand Access to Pharmaceuticals during National Emergencies. Journal of Science Policy & Governance, 2021, 18, .	0.2	0
36	Discovery and Development of Pregabalin (Lyrica). Neurology, 2021, 97, e1653-e1660.	1.1	1
37	Responsible innovation in biotechnology: Stakeholder attitudes and implications for research policy. Elementa, 2020, 8, .	3.2	13
39	Political and Economic Aspects of Academic and Educational Entrepreneurship. Springer Texts in Business and Economics, 2022, , 49-65.	0.3	0

#	ARTICLE	IF	CITATIONS
40	Drug discovery processes: When and where the rubber meets the road. , 2023, , 339-415.		1
41	Trends in Ophthalmological Patents, 2005â€“2020. Journal of Ocular Pharmacology and Therapeutics, 0, , .	1.4	0
43	Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019. JAMA Health Forum, 2023, 4, e230511.	2.2	7
44	Fiduciary responsibility. Drug Discovery Today, 2023, 28, 103794.	6.4	0
45	Training the Innovative Gastroenterologist of the Future: Establishing a Formal Curriculum During Gastroenterology Fellowship. Gastroenterology, 2024, 166, 16-20.e1.	1.3	0